An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis

¹ Department of Neurological Sciences, La Sapienza University, Rome, Italy
² New York Medical College, Valhalla, NY 10595, USA

^* To whom correspondence should be addressed.

	Abstract

Sixty-two patients with multiple sclerosis (MS) were imaged monthly over a six-month (ie, seven monthly magnetic resonance images [MRI]) natural history period (NHP). Thereafter, patients were randomized to receive 11 or 33µg of subcutaneously injected interferon beta 1a (IFNbeta-1a) with imaging monthly for nine months and at months 12, 18 and 24 of therapy phase (TP). In the present exploratory post hoc analysis, the authors evaluated IFNbeta-1a dose effect on reducing the size of contrast-enhancing lesions (CELs). MRIs performed at months 0, 3 and 6 of NHP and at months 3, 6, 9, 18 and 24 of TP were analysed. While a significant reduction in mean number of CELs was observed in both treatment groups of patients, the mean total volume and size of CELs was reduced only in patients undergoing therapy with 33µg of IFNbeta-1a. The latter suggests a significant dose effect exerted by IFNbeta-1a in the evolution of CELs' dimensions during therapy.

Key Words: contrast-enhancing lesions, inflammation, interferon beta, lesion size, magnetic resonance imaging, multiple sclerosis

First published on January 29, 2007, doi:10.1177/1352458506071172

Multiple Sclerosis 2007;13:343.

A more recent version of this article appeared on April 1, 2007


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?